66. IgA nephropathy Clinical trials / Disease details


Clinical trials : 275 Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2200058382
2018-12-012022-04-07Influence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA NephropathyInfluence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA Nephropathy IgA NephropathyControl group:Losartan potassium and other basic western treatment;Observation group:On the basis of control group, IgA nephropathy I prescription was combined orally;Healthy control group:None;Hu QianqianNULLCompleted1865BothControl group:45;Observation group:45;Healthy control group:20;China
2ITMCTR2200005824
2018-12-012022-04-07Influence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA NephropathyInfluence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA Nephropathy IgA NephropathyControl group:Losartan potassium and other basic western treatment;Healthy control group:None;Observation group:On the basis of control group, IgA nephropathy I prescription was combined orally;HuQianqianNULLCompleted1865BothControl group:45;Healthy control group:20;Observation group:45;China
3ChiCTR-IIR-17013487
2018-01-012017-11-22A multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantabA multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantab IgA nephropathyExperimental group:Zhengqing Fengtongning extantab;Control group 1:Losartan Potassium Tablets;Control group 2:Losartan Potassium Tablets + Zhengqing Fengtongning extantab;The Third Xiangya Hospital of Central South UniversityNULLRecruiting1870BothExperimental group:36;Control group 1:36;Control group 2:36;4 (Phase 4 study)China